美托洛尔缓释片联合沙库巴曲缬沙坦钠片治疗高血压合并心衰患者临床疗效的观察

doi:10.3969/j.issn.1006-6233.2023.12.030

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1217 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the clinical efficacy of metoprolol succinate sustained-release tablets combined with sacubitril valsartan tablets in the treatment of hypertension complicated with heart failure. Methods: A total of 135 patients with hypertension complicated with heart failure admitted to our hospital from January 2020 to January 2023 were selected. According to the order of admission, they were divided into the Bisoprolol Group (odd numbers, conventional treatment + metoprolol sustained-release tablets) with 68 cases and the Sacubitril Group (even numbers, based on the Bisoprolol Group + sacubitril valsartan tablets) with 67 cases, using single and double numbers. The treatment effects, blood pressure, heart rate, cardiac function indicators, vascular endothelial function, and levels of cardiac troponin I (cTnI) and N-terminal pro-brain natriuretic peptide (NT-BNP) before and after treatment were compared between the two groups. Adverse reactions during the treatment period were recorded. Results: The total effective rate in the Sacubitril Group was higher than that in the Bisoprolol Group (97.01% vs 86.76%) (P<0.05). After treatment, both groups showed a significant reduction in systolic and diastolic blood pressure, heart rate, left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), endothelin (ET), cTnI, and NT-BNP (P<0.05). Left ventricular ejection fraction (LVEF), nitric oxide (NO), and calcitonin gene-related peptide (CGRP) increased (P<0.05). The differences before and after treatment between the two groups were statistically significant (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: The combination of metoprolol sustained-release tablets and sacubitril valsartan sodium is significantly effective in treating hypertension with heart failure. This treatment can effectively control blood pressure, improve cardiac function and vascular endothelial function, and reduce levels of cTnI and NT-BNP. It is worthy of promotion and application in clinical practice.

Key words： Metoprolol succinate sustained-release tablets Sacubitril valsartan tablets

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2023.12.030 OR http://www.hbyxzzs.cn/EN/Y2023/V29/I12/2092

[1] 李艳娜,薛雯雯,赵梦瑜.乌拉地尔与酒石酸美托洛尔治疗高血压合并心力衰竭的临床疗效观察[J].中国临床医生杂志,2020,48(6):659-662.
[2] 赖朝辉,刘迎午,王禹,等.沙库巴曲缬沙坦钠对射血分数减低的心力衰竭合并高血压患者血压及相关指标变化的研究[J].中华老年心脑血管病杂志,2022,24(1):11-13.
[3] 夏勇,张建卿,王少霞,等.沙库巴曲缬沙坦联合美托洛尔缓释片治疗冠状动脉粥样硬化性心脏病并慢性心力衰竭的效果观察[J].首都医科大学学报,2020,41(1):113-118.
[4] 中国高血压防治指南修订委员会,高血压联盟(中国,中华医学会心血管病学分会中国医师协会高血压专业委员会,等.中国高血压防治指南(2018年修订版)[J].中国心血管杂志,2019,24(1):24-56.
[5] 中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.
[6] 侯绪英,杨红,房修燕,等.厄贝沙坦与硝普钠联合治疗高血压合并心衰对患者心率、血管内皮功能、TNF-α及hs-CRP水平的影响[J].中国循证心血管医学杂志,2023,15(3):329-332.
[7] 李琚平,管文娟,黄占宏.沙库巴曲缬沙坦钠片联合美托洛尔缓释片治疗慢性心力衰竭的效果分析[J].中国实用医刊,2023,50(4):97-100.
[8] 张洪旭,陈瞳,张利方,等.沙库巴曲缬沙坦钠对老年射血分数保留型心力衰竭伴高血压患者血浆同型半胱氨酸和尿酸的影响及预后研究[J].中国心血管病研究,2023,21(7):638-645.
[9] 董萌.沙库巴曲缬沙坦钠治疗老年慢性心力衰竭合并肾功能不全患者的临床观察[J].中国中西医结合急救杂志,2020,27(1):84-87.
[10] 周志强,于海峰,齐燕,等.美托洛尔联合沙库巴曲缬沙坦钠治疗慢性心力衰竭的效果及其对血清NT-proBNP和炎症因子的影响[J].中国老年学杂志,2023,43(9):2070-2073.